SCHEMBL5714786

SCHEMBL5714786

Cc1ccc(CCCN2CCN(C(=O)Oc3ccc(CCc4ccc(C)cn4)cc3)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.47
HTR2A P28223 2/20 0.47
HTR7 P34969 2/20 0.47
ADORA3 P0DMS8 1/20 0.47
OPRM1 P35372 1/20 0.47
AOC3 Q16853 1/20 0.46
DRD2 P14416 2/20 0.46
FAAH O00519 5/20 0.42
MGLL Q99685 2/20 0.42
HRH2 P25021 5/20 0.42
HRH1 P35367 5/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTR1A P08908 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41
HTR2C P28335 1/20 0.41
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715262 0.94 AOC3 (0.48) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5714965 0.93 SIGMAR1 (0.46) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5714936 0.93 DRD2 (0.45) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5714958 0.93 SIGMAR1 (0.44) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5714472 0.93 SIGMAR1 (0.42) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5715186 0.92 SIGMAR1 (0.43) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5715373 0.92 SIGMAR1 (0.43) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5715419 0.90 KDM4E (0.47) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5714564 0.89 SIGMAR1 (0.43) SIGMAR1HTR2AHTR7ADORA3OPRM1
SCHEMBL5714964 0.89 HRH2 (0.52) SIGMAR1HTR2AHTR7ADORA3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL SIGMAR1 2726/4885HTR2A 1618/4885HTR7 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.